Inthera Bioscience

Executive Summary

Inthera Bioscience AG is a Swiss biotechnology company founded in 2017 and headquartered in Zurich. The company is focused on developing novel small molecule therapies that exploit replication stress in cancer cells, a vulnerability that is particularly pronounced in many advanced malignancies. Its lead candidate, INTH-454, is an IND-ready compound targeting the Negative Elongation Factor (NELF) complex, which plays a critical role in transcription elongation and genome stability. By inhibiting NELF, INTH-454 selectively disrupts the replication stress response in cancer cells while sparing normal cells, offering a potentially differentiated therapeutic approach. The compound is poised to enter clinical development, with preclinical data supporting its mechanism and safety profile. Inthera's platform represents a promising strategy in the oncology space, addressing a validated but underexploited target. The company is privately held and has not disclosed fundraising details, but its lead asset is at a pivotal stage, making it an attractive candidate for further development or partnership.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for INTH-45470% success
• Q4 2026Phase 1 Clinical Trial Initiation65% success
• TBDPartnership or Licensing Deal40% success